Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TG Therapeutics, Inc., Intellia Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how TG Therapeutics, Inc., Intellia Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About TG Therapeutics, Inc., Intellia Therapeutics and Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and TG Therapeutics, Inc., Intellia Therapeutics, Inc. Stock News

As of September 9, 2026, TG Therapeutics, Inc. had a $7.8 billion market capitalization, compared to the Biotechnology median of $279.4 million. TG Therapeutics, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 68.78% in the past year.

Currently, TG Therapeutics, Inc.’s price-earnings ratio is 19.7. TG Therapeutics, Inc.’s trailing 12-month revenue is $799.5 million with a 55.2% net profit margin. Year-over-year quarterly sales growth most recently was 70.3%. Analysts expect adjusted earnings to reach $0.950 per share for the current fiscal year. TG Therapeutics, Inc. does not currently pay a dividend.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $59.5 million with a -672.2% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.157 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

How We Compare TG Therapeutics, Inc., Intellia Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TG Therapeutics, Inc., Intellia Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

TG Therapeutics, Inc., Intellia Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
TG Therapeutics, Inc.	TGTX	F
Intellia Therapeutics, Inc.	NTLA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

TG Therapeutics, Inc. has a Growth Score of 18, which is Very Weak. Intellia Therapeutics, Inc. has a Growth Score of 17, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc., Intellia Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc., Intellia Therapeutics or Inc. is the better investment when it comes to sustainable growth.

TG Therapeutics, Inc., Intellia Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
TG Therapeutics, Inc.	TGTX	A
Intellia Therapeutics, Inc.	NTLA	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

TG Therapeutics, Inc. has a Momentum Score of 86, which is Very Strong. Intellia Therapeutics, Inc. has a Momentum Score of 50, which is Average.

The Momentum Grade Winner: TG Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, TG Therapeutics, Inc. is considered to have stronger momentum compared to Intellia Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, TG Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

TG Therapeutics, Inc., Intellia Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
TG Therapeutics, Inc.	TGTX	F
Intellia Therapeutics, Inc.	NTLA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

TG Therapeutics, Inc. has a Earnings Estimate Score of 12, which is Very Negative. Intellia Therapeutics, Inc. has a Earnings Estimate Score of 35, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc., Intellia Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc., Intellia Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other TG Therapeutics, Inc., Intellia Therapeutics and Inc. Grades

In addition to Estimate Revisions, Momentum and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether TG Therapeutics, Inc., Intellia Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, TG Therapeutics, Inc., Intellia Therapeutics or Inc. Stock?

Overall, TG Therapeutics, Inc. stock has a Growth Score of 18, Momentum Score of 86 and Estimate Revisions Score of 12.

Intellia Therapeutics, Inc. stock has a Growth Score of 17, Momentum Score of 50 and Estimate Revisions Score of 35.

Comparing TG Therapeutics, Inc., Intellia Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.